메뉴 건너뛰기
Canadian Journal of Diabetes
Volumn 38, Issue 4, 2014, Pages 269-272
Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy
Author keywords

Diabetes; Diab te; Exenatide; Ex natide; GLP 1 (glucagon like peptide 1); Glucagon like peptide 1; Incretin; Incr tine
Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN; EXENATIDE; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;
EID: 84905251216     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.10.006     Document Type: Article
Times cited : (39)
References (8)
  • 1
    • 77952758235 scopus 로고    scopus 로고
    • Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
    • Kielgast U., Asmar M., Madsbad S., et al. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. JClin Endocrinol Metab 2010, 95:2492-2496.
    • (2010) JClin Endocrinol Metab , vol.95 , pp. 2492-2496
    • Kielgast, U.1    Asmar, M.2    Madsbad, S.3
  • 2
    • 0016888063 scopus 로고
    • Regulation of pancreatic insulin and glucagon secretion
    • Gerich J.E., Charles M.A., Grodsky G.M. Regulation of pancreatic insulin and glucagon secretion. Annu Rev Physiol 1976, 38:353-388.
    • (1976) Annu Rev Physiol , vol.38 , pp. 353-388
    • Gerich, J.E.1    Charles, M.A.2    Grodsky, G.M.3
  • 3
    • 3242664057 scopus 로고    scopus 로고
    • Exendin-4 normalized postcibal glycemic excursions in type 1 diabetics
    • Dupré J., Behme M.T., McDonald T.J. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetics. JClin Endocrinol Metab 2004, 89:3469-3473.
    • (2004) JClin Endocrinol Metab , vol.89 , pp. 3469-3473
    • Dupré, J.1    Behme, M.T.2    McDonald, T.J.3
  • 4
    • 77956074558 scopus 로고    scopus 로고
    • The role of adjunctive exenatide therapy in pediatric type 1 diabetes
    • Raman V.S., Mason K.J., Rodriguez L.M., et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010, 33:1294-1296.
    • (2010) Diabetes Care , vol.33 , pp. 1294-1296
    • Raman, V.S.1    Mason, K.J.2    Rodriguez, L.M.3
  • 5
    • 80054690193 scopus 로고    scopus 로고
    • Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function
    • Kielgast U., Holst J.J., Krarup T., et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care 2011, 34:1463-1468.
    • (2011) Diabetes Care , vol.34 , pp. 1463-1468
    • Kielgast, U.1    Holst, J.J.2    Krarup, T.3
  • 6
    • 79959392262 scopus 로고    scopus 로고
    • Liraglutide as additional treatment in type 1 diabetes
    • Varanasi A., Bellini N., Rawal D., et al. Liraglutide as additional treatment in type 1 diabetes. Eur J Endocrinol 2011, 165:77-84.
    • (2011) Eur J Endocrinol , vol.165 , pp. 77-84
    • Varanasi, A.1    Bellini, N.2    Rawal, D.3
  • 7
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study
    • Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
    • (2008) Lancet , vol.372 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 8
    • 67651173077 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus
    • Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
    • (2009) Nat Rev Endocrinol , vol.5 , pp. 262-269
    • Lovshin, J.A.1    Drucker, D.J.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.